The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
IBS-C
A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
1 other identifier
interventional
1,054
1 country
155
Brief Summary
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2014
155 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 20, 2015
CompletedFirst Posted
Study publicly available on registry
March 13, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedResults Posted
Study results publicly available
June 14, 2019
CompletedJune 14, 2019
June 1, 2019
2 years
January 20, 2015
May 23, 2019
June 13, 2019
Conditions
Outcome Measures
Primary Outcomes (3)
Number of Overall Responders - ITT Population
An Overall Responder was a patient who was a Weekly Responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least one complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.
12 Weeks
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks
An Abdominal Pain Intensity Responder was a patient who had a decrease of 30% from baseline for abdominal pain intensity. Baseline was the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
12 Weeks
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks
A Stool Frequency Responder is defined as a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
12 weeks
Secondary Outcomes (6)
Number of Sustained Efficacy Responders
12 weeks
Change From Baseline in Stool Consistency
Baseline and 12-Week
Change From Baseline in Straining
Baseline and 12-week
Change From Baseline in CSBM Frequency Rate
Baseline and 12-Week
Number of Patients With a SBM Within 24 Hours After the First Dose
Up to 24 hours after first dose of study drug
- +1 more secondary outcomes
Study Arms (3)
3.0 mg plecanatide
ACTIVE COMPARATORPlecanatide 3.0 mg dosed daily for 12 weeks
6.0 mg plecanatide
ACTIVE COMPARATORPlecanatide 6.0 mg dosed daily for 12 weeks
Matching placebo
ACTIVE COMPARATORPlacebo dosed daily for 12 weeks
Interventions
Eligibility Criteria
You may qualify if:
- Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C
You may not qualify if:
- Refusal or inability to sign informed consent for the trial
- Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires
- BMI \> 35 or \< 18
- Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial
- Women who are pregnant or lactating
- Diagnosis of IBS-D or IBS-M
- Organic or obstructive disease of the small or large intestine
- Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)
- Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication
- Unstable medical illness
- Bilirubin \> 3X ULN in the absence of a conjugation defect
- Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (155)
Synergy Research Site
Athens, Alabama, 35611, United States
Synergy Research Site
Birmingham, Alabama, 35242, United States
Synergy Research Site
Dothan, Alabama, 36305, United States
Synergy Research Site
Foley, Alabama, 36535, United States
Synergy Research Site
Huntsville, Alabama, 35801, United States
Synergy Research Site
Montgomery, Alabama, 36106, United States
Synergy Research Site
Chandler, Arizona, 85224, United States
Synergy Research Site
Glendale, Arizona, 85308, United States
Synergy Research Site
Phoenix, Arizona, 85018, United States
Synergy Research Site
Tucson, Arizona, 85710, United States
Synergy Research Site
Tucson, Arizona, 85712, United States
Synergy Research Site
Conway, Arkansas, 72034, United States
Synergy Research Site
Little Rock, Arkansas, 72211, United States
Synergy Research Site
Little Rock, Arkansas, 72212, United States
Synergy Research Site
Anaheim, California, 92801, United States
Synergy Research Site
Artesia, California, 90701, United States
Synergy Research Site
Chula Vista, California, 91910, United States
Synergy Research Site
Corona, California, 92879, United States
Synergy Research Site
Encino, California, 91436, United States
Synergy Research Site
Fountain Valley, California, 92708, United States
Synergy Research Site
Fresno, California, 93702, United States
Synergy Research Site
Garden Grove, California, 92840, United States
Synergy Research Site
La Mesa, California, 91942, United States
Synergy Research Site
La Mirada, California, 90638, United States
Synergy Research Site
Laguna Hills, California, 92653, United States
Synergy Research Site
Lancaster, California, 93534, United States
Synergy Research Site
North Hollywood, California, 91606, United States
Synergy Research Site
Sacramento, California, 95821, United States
Synergy Research Site
San Bernardino, California, 92408, United States
Synergy Research Site
San Diego, California, 92103, United States
Synergy Research Site
Thousand Oaks, California, 91360, United States
Synergy Research Site
Upland, California, 91786, United States
Synergy Research Site
Upland, California, United States
Synergy Research Site
Broomfield, Colorado, United States
Synergy Research Site.
Centennial, Colorado, 80112, United States
Synergy Research Site
Bristol, Connecticut, 06010, United States
Synergy Research Site
Hamden, Connecticut, 06518, United States
Synergy Research Site
Boynton Beach, Florida, 33426, United States
Synergy Research Site
Brandon, Florida, 33511, United States
Synergy Research Site
DeLand, Florida, 32720, United States
Synergy Research Site
Fort Lauderdale, Florida, 33308, United States
Synergy Research Site
Homestead, Florida, 33030, United States
Synergy Research Site
Inverness, Florida, 34452, United States
Synergy Research Site
Jacksonville, Florida, 32205, United States
Synergy Research Site
Miami, Florida, 33144, United States
Synergy Research Site
Miami Lakes, Florida, 33014, United States
Synergy Research Site
Miami Springs, Florida, 33166, United States
Synergy Research Site
Orlando, Florida, 32801, United States
Synergy Research Site
Ormond Beach, Florida, 32174, United States
Synergy Research Site
Oviedo, Florida, 32765, United States
Synergy Research Site
Port Orange, Florida, 32129, United States
Synergy Research Site
St. Petersburg, Florida, 33709, United States
Synergy Research Site
Tampa, Florida, 33607, United States
Synergy Research Site
Atlanta, Georgia, 30328, United States
Synergy Research Site
Marietta, Georgia, 30060, United States
Synergy Research Site
Norcross, Georgia, 30071, United States
Synergy Research Site
Norcross, Georgia, 30092, United States
Synergy Research Site
Stockbridge, Georgia, 30281, United States
Synergy Research Site
Idaho Falls, Idaho, 83404, United States
Synergy Research Site
Idaho Falls, Idaho, United States
Synergy Research Site
Chicago, Illinois, 60611, United States
Synergy Research Site
Evanston, Illinois, 60201, United States
Synergy Research Site
Evergreen Park, Illinois, 60805, United States
Synergy Research Site
Rockford, Illinois, 61107, United States
Synergy Research Site
Evansville, Indiana, 47714, United States
Synergy Research Site
Augusta, Kansas, 67010, United States
Synergy Research Site
Newton, Kansas, 67114, United States
Synergy Research Site
Topeka, Kansas, 66606, United States
Synergy Research Site
Wichita, Kansas, 67205, United States
Synergy Research Site
Wichita, Kansas, 67207, United States
Synergy Research Site
Baton Rouge, Louisiana, 70809, United States
Synergy Research Site
Crowley, Louisiana, 70526, United States
Synergy Research Site
Mandeville, Louisiana, 70448, United States
Synergy Research Site
Metairie, Louisiana, 70006, United States
Synergy Research Site
Monroe, Louisiana, 71201, United States
Synergy Research Site
New Orleans, Louisiana, 70115, United States
Synergy Research Site
Shreveport, Louisiana, 71105, United States
Synergy Research Site
Baltimore, Maryland, 21215, United States
Synergy Research Site
Hagerstown, Maryland, 21742, United States
Synergy Research Site
Boston, Massachusetts, 02131, United States
Synergy Research Site
Chesterfield, Michigan, 48047, United States
Synergy Research Site
Flint, Michigan, 48504, United States
Synergy Research Site
Rochester, Michigan, 48307, United States
Synergy Research Site
Wyoming, Michigan, 49519, United States
Synergy Research Site.
Jackson, Mississippi, United States
Synergy Research Site
Hazelwood, Missouri, 63042, United States
Synergy Research Site
Omaha, Nebraska, 68134, United States
Synergy Research Site
Las Vegas, Nevada, 89119, United States
Synergy Research Site
Marlton, New Jersey, 08053, United States
Synergy Research Site
Albuquerque, New Mexico, 87108, United States
Synergy Research Site
Brooklyn, New York, 11206, United States
Synergy Research Site
Great Neck, New York, 11023, United States
Synergy Research Site
New Windsor, New York, 12553, United States
Synergy Research Site
New York, New York, 10016, United States
Synergy Research Site
North Massapequa, New York, 11758, United States
Synergy Research Site
Asheboro, North Carolina, 27203, United States
Synergy Research Site
Cary, North Carolina, 27513, United States
Synergy Research Site
Charlotte, North Carolina, 28210, United States
Synergy Research Site
Charlotte, North Carolina, 28277, United States
Synergy Research Site
Concord, North Carolina, 28025, United States
Synergy Research Site
Davidson, North Carolina, 28036, United States
Synergy Research Site
Greensboro, North Carolina, 27403, United States
Synergy Research Site
Kinston, North Carolina, 28501, United States
Synergy Research Site
Lenoir, North Carolina, 28645, United States
Synergy Research Site
Raleigh, North Carolina, 27612, United States
Synergy Research Site
Wilmington, North Carolina, 28401, United States
Synergy Research Site
Winston-Salem, North Carolina, 27103, United States
Synergy Research Site
Fargo, North Dakota, 58103, United States
Synergy Research Site
Beavercreek, Ohio, 45440, United States
Synergy Research Site
Cincinnati, Ohio, 45212, United States
Synergy Research Site
Cleveland, Ohio, 44122, United States
Synergy Research Site
Cleveland, Ohio, United States
Synergy Research Site
Englewood, Ohio, 45322, United States
Synergy Research Site
Sylvania, Ohio, 43560, United States
Synergy Research Site
Oklahoma City, Oklahoma, 73102, United States
Synergy Research Site
Tulsa, Oklahoma, 74135, United States
Synergy Research Site
Portland, Oregon, 97210, United States
Synergy Research Site
Levittown, Pennsylvania, 19056, United States
Synergy Research Site
Philadelphia, Pennsylvania, 19152, United States
Synergy Research Site
Pittsburgh, Pennsylvania, 15206, United States
Synergy Research Site
Smithfield, Pennsylvania, 15478, United States
Synergy Research Site
Uniontown, Pennsylvania, 15401, United States
Synergy Research Site
Columbia, South Carolina, 29204, United States
Synergy Research Site
Gaffney, South Carolina, 29341, United States
Synergy Research Site.
Greer, South Carolina, 29650, United States
Synergy Research Site
North Charleston, South Carolina, 29406, United States
Synergy Research Site
Rapid City, South Dakota, 57702, United States
Synergy Research Site
Athens, Tennessee, 37303, United States
Synergy Research Site
Chattanooga, Tennessee, 37404, United States
Synergy Research Site
Memphis, Tennessee, 38119, United States
Synergy Research Site.
Nashville, Tennessee, 37211, United States
Synergy Research Site
Arlington, Texas, United States
Synergy Research Site
Austin, Texas, 78756, United States
Synergy Research Site
Austin, Texas, 78758, United States
Synergy Research Site
Carrollton, Texas, 75010, United States
Synergy Research Site
Dallas, Texas, 75230, United States
Synergy Research Site
Houston, Texas, 77074, United States
Synergy Research Site
Houston, Texas, 77099, United States
Synergy Research Site
Plano, Texas, 75093, United States
Synergy Research Site
San Antonio, Texas, 78229, United States
Synergy Research Site
Webster, Texas, 77598, United States
Synergy Research Site
Bountiful, Utah, 84010, United States
Synergy Research Site
Ogden, Utah, 84405, United States
Synergy Research Site
Sandy City, Utah, 84092, United States
Synergy Research Site
St. George, Utah, 84790, United States
Synergy Research Site
Alexandria, Virginia, 22304, United States
Synergy Research Site
Charlottesville, Virginia, 22911, United States
Synergy Research Site
Lynchburg, Virginia, 24502, United States
Synergy Research Site
Newport News, Virginia, 23606, United States
Synergy Research Site
Bellevue, Washington, 98004, United States
Synergy Research Site
Spokane, Washington, 99208, United States
Synergy Research Site
Charleston, West Virginia, 25304, United States
Synergy Research Site
Morgantown, West Virginia, 26505, United States
Synergy Research Site
Milwaukee, Wisconsin, 53215, United States
Synergy Research Site
Wauwatosa, Wisconsin, 53226, United States
Related Publications (3)
Brenner DM, Shin AS, Laitman AP, Deutsch JK, Kunkel DC. The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint. J Gastroenterol Hepatol. 2025 Dec;40(12):2890-2897. doi: 10.1111/jgh.70119. Epub 2025 Nov 10.
PMID: 41214272DERIVEDCash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.
PMID: 37332239DERIVEDMenees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.
PMID: 32660770DERIVED
MeSH Terms
Interventions
Results Point of Contact
- Title
- VP Regulatory Affairs & Clinical QA
- Organization
- Synergy Pharmaceuticals Inc.
Study Officials
- STUDY DIRECTOR
Paul F.C. Eng, PhD
Synergy Pharmaceuticals Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 20, 2015
First Posted
March 13, 2015
Study Start
December 1, 2014
Primary Completion
December 1, 2016
Study Completion
February 1, 2017
Last Updated
June 14, 2019
Results First Posted
June 14, 2019
Record last verified: 2019-06